NJ Adopts ERT Solution for Suicide Monitoring in Students
ERT, a leading provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, today announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University
ERT, a provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University Behavioral Health Care (UBHC) as part of the New Jersey Youth Suicide Prevention Project (NJYSPP). Beginning this semester, AVERT will be used to identify and routinely assess suicide risk among high school and college students in six targeted NJ counties (Bergen, Camden, Hudson, Passaic, Middlesex and Monmouth). Suicide is the second leading cause of death among 15 to 24 year olds in the United States (2012). Funded by a grant administered by the Substance Abuse and Mental Health Services Administration, the NJYSPP is a comprehensive approach to youth suicide prevention, which provides gatekeepers in the counties with best-practice and evidence-based trainings in suicide prevention, intervention, and postvention at no charge. By using the AVERT self-assessment system, the NJYSPP’s objective is to help school-based gatekeepers proactively identify at-risk students and more efficiently refer them to trained mental health professionals in their community. Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
